GeneDx Holdings Corp. (NASDAQ:WGS) Shares Sold by Trexquant Investment LP

Trexquant Investment LP reduced its position in GeneDx Holdings Corp. (NASDAQ:WGS) by 38.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 74,912 shares of the company’s stock after selling 47,100 shares during the period. Trexquant Investment LP owned 0.27% of GeneDx worth $5,758,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the company. William Blair Investment Management LLC acquired a new stake in shares of GeneDx in the 4th quarter worth $51,496,000. Zweig DiMenna Associates LLC acquired a new position in GeneDx during the fourth quarter worth about $23,788,000. Raymond James Financial Inc. purchased a new stake in GeneDx in the 4th quarter valued at approximately $20,371,000. Vanguard Group Inc. lifted its position in shares of GeneDx by 18.5% in the fourth quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company’s stock valued at $77,337,000 after acquiring an additional 156,768 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in GeneDx in the 4th quarter valued at about $10,821,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

WGS has been the topic of a number of recent analyst reports. TD Cowen increased their price target on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, January 7th. The Goldman Sachs Group lifted their price target on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $72.33.

GeneDx Stock Performance

NASDAQ:WGS opened at $80.02 on Friday. GeneDx Holdings Corp. has a 1-year low of $8.63 and a 1-year high of $115.60. The firm has a 50-day moving average of $88.11 and a two-hundred day moving average of $75.56. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The stock has a market cap of $2.25 billion, a P/E ratio of -40.83 and a beta of 1.91.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.66. The company had revenue of $95.64 million during the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. On average, research analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Insider Activity at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 35,506 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $93.82, for a total transaction of $3,331,172.92. Following the completion of the transaction, the chief financial officer now directly owns 2,472 shares of the company’s stock, valued at $231,923.04. The trade was a 93.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Katherine Stueland sold 1,657 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $78.48, for a total value of $130,041.36. Following the completion of the sale, the chief executive officer now owns 3,937 shares in the company, valued at approximately $308,975.76. This represents a 29.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 163,596 shares of company stock valued at $15,490,752. Corporate insiders own 27.30% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.